The Rising Influence of Rising Affluence

[biocqr]

I have no idea what your referring to wrt spikes.

My point was to get Jim's perspective on this preclinical study which seems to cast some doubt on VK2809 drug-drug interactions at least wrt to statins.

from the research paper...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697679/

Potential drug–drug interactions
The conversion of atorvastatin and its inactive metabolite, atorvastatin lactone, to their corresponding hydroxy acids by CYP3A4 is their major clearance pathway in vivo (Jacobsen et al., 2000). Similarly, the activation of the MB07811 prodrug to the active TR agonist MB07344 is dependent upon hepatic CYP3A4-mediated cleavage (Erion et al., 2004; 2007). In recognition of this common pathway, a potential drug–drug interaction was assessed early in the development of MB07811. In vitro studies indicated that neither MB07344 nor MB07811 inhibited CYP3A-mediated testosterone-6ß-hydroxylation in human liver microsomes (Fujitaki, unpubl. obs.). Additionally, results from the monkey study reported herein showed no change in the plasma AUC or Cmax of either drug or their metabolites when administered in combination for 8 days at therapeutic doses, when compared with each drug administered individually. These results indicate that MB07811 does not suppress or induce CYP3A-mediated metabolism of atorvastatin. This finding is not surprising given that hepatic concentrations of HepDirect prodrugs rise only transiently and remain far below their Km for CYP3A due to efficient conversion to the phosphonic acid.